The European Union's health regulator on Friday backed AstraZeneca and Daiichi Sankyo's drug Enhertu as a breast cancer ...

but MSD (known as Merck & Co in the US and Canada) paid $20 million upfront to Alteogen, with up to $432 million in back-end milestones. Enhertu is fast becoming a major growth product for Daiichi ...

Canada and Europe as part of a $4.2 billion alliance signed between the companies last year. The deal with RemeGen gives Seagen a closer rival to AZ and Daiichi Sankyo's Enhertu (trastuzumab ...

AstraZeneca’s Imfinzi (durvalumab) in combination with chemotherapy has been recommended for approval in the European Union (EU) for the treatment of adults with resectable non-small cell lung cancer ...

EMA committee recommends approval of AstraZeneca’s Imfinzi in combo with chemotherapy to treat resectable non-small cell lung cancer ...

The trial demonstrated that Enhertu, a HER2-directed antibody drug conjugate (ADC), significantly reduced the risk of disease progression or death by 38% compared to chemotherapy, achieving a ...

TOKYO & MUNICH - Daiichi Sankyo (TSE: 4568) and AstraZeneca (LSE/STO/Nasdaq: NASDAQ:AZN) have announced that their drug ENHERTU (trastuzumab deruxtecan) has been recommended for approval in the ...

Callio Therapeutics is launching with an ADC technology and programs licensed from Singapore-based antibody drug developer Hummingbird Bioscience.

ADCs are currently at the forefront of cancer treatment, but persistent drug development challenges call for a new approach.

Mark Erlander; Chief Executive Officer, Director; Cardiff Oncology Inc. James Levine; Chief Financial Officer; Cardi ...